These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 27232760)

  • 1. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
    Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
    MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
    Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
    MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Human Pharmacokinetics Profile of Monoclonal Antibody Using hFcRn Transgenic Mouse Model.
    Nakamura G; Ozeki K; Takesue H; Tabo M; Hosoya KI
    Biol Pharm Bull; 2021; 44(3):389-395. PubMed ID: 33642546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.
    Tam SH; McCarthy SG; Brosnan K; Goldberg KM; Scallon BJ
    MAbs; 2013; 5(3):397-405. PubMed ID: 23549129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics.
    Myzithras M; Bigwarfe T; Li H; Waltz E; Ahlberg J; Giragossian C; Roberts S
    MAbs; 2016; 8(8):1606-1611. PubMed ID: 27598372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Analysis of Human Neonatal Fc Receptor (FcRn) Tissue Expression in Transgenic Mice by Online Peptide Immuno-Affinity LC-HRMS.
    Fan YY; Neubert H
    Anal Chem; 2016 Apr; 88(8):4239-47. PubMed ID: 27012525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics.
    Avery LB; Wade J; Wang M; Tam A; King A; Piche-Nicholas N; Kavosi MS; Penn S; Cirelli D; Kurz JC; Zhang M; Cunningham O; Jones R; Fennell BJ; McDonnell B; Sakorafas P; Apgar J; Finlay WJ; Lin L; Bloom L; O'Hara DM
    MAbs; 2018; 10(2):244-255. PubMed ID: 29271699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.
    Fan YY; Avery LB; Wang M; O'Hara DM; Leung S; Neubert H
    MAbs; 2016 Jul; 8(5):848-53. PubMed ID: 27104806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data.
    Jones HM; Zhang Z; Jasper P; Luo H; Avery LB; King LE; Neubert H; Barton HA; Betts AM; Webster R
    CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):738-747. PubMed ID: 31464379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.
    Haraya K; Tachibana T; Nanami M; Ishigai M
    Xenobiotica; 2014 Dec; 44(12):1127-34. PubMed ID: 25030041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Physiologically-Based Pharmacokinetic Model for the Prediction of "Half-Life Extension" and "Catch and Release" Monoclonal Antibody Pharmacokinetics.
    Jones HM; Tolsma J; Zhang Z; Jasper P; Luo H; Weber GL; Wright K; Bard J; Bell R; Messing D; Kelleher K; Piche-Nicholas N; Webster R
    CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):534-541. PubMed ID: 32697437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of cassette-dosing and microsampling for reduced animal usage for antibody pharmacokinetics in cynomolgus monkeys, wild-type mice, and human FcRn transgenic mice.
    Nagayasu M; Ozeki K
    Pharm Res; 2021 Apr; 38(4):583-592. PubMed ID: 33782838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studies.
    Conner CM; van Fossan D; Read K; Cowley DO; Alvarez O; Xu SX; Webb DR; Jarnagin K
    Biochem Pharmacol; 2023 Apr; 210():115470. PubMed ID: 36870576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies.
    Roopenian DC; Christianson GJ; Proetzel G; Sproule TJ
    Methods Mol Biol; 2016; 1438():103-14. PubMed ID: 27150086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.
    Kliwinski C; Cooper PR; Perkinson R; Mabus JR; Tam SH; Wilkinson TM; Giles-Komar J; Scallon B; Powers GD; Hornby PJ
    Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(3):G262-70. PubMed ID: 23220220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
    Proetzel G; Roopenian DC
    Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.